This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Columbyova, L. Articles by Scadden, D. T. Search for Related Content PubMed PubMed Citation Articles by Columbyova, L. Articles by Scadden, D. T.

Thrombopoietin Receptor Expression in Human Cancer Cell Lines and Primary Tissues

Division of Hematology/Oncology, Department of Medicine [L. C., M. L., D. T. S.], and Department of Pathology [M. L.], New England Deaconess Hospital, Harvard Medical School, Boston, Massachusetts 02215

c-mpl is the receptor for the recently identified megakaryocyte growth and differentiation factor thrombopoietin. Thrombopoietin has been shown to be capable of raising platelet counts in animals and is about to enter clinical trials in humans. In anticipation of its likely use in the care of patients receiving cancer chemotherapy, we evaluated the expression of human c-mpl by reverse transcription PCR on 39 human cell lines and 20 primary human tissue samples derived from both normal and malignant sources. c-mpl transcripts were found in all megakaryocytic cell lines tested (CMK, CMK-2B, CMK-2D, SO, and DAMI), the CD34+ leukemia cell line KMT-2, and a hepatocellular carcinoma cell line (Hep3B). Among primary tissues, fetal liver cells and brain had detectable levels of c-mpl message, and among primary tumors, none were found to express c-mpl. These data support the conclusion that c-mpl has restricted expression that is primarily, but not exclusively, related to megakaryocytopoiesis. These observations suggest that thrombopoietin is unlikely to have direct effects on other malignant or normal tissue should it have a clinical role in the treatment of chemotherapy-induced thrombocytopenia.

¹ To whom requests for reprints should be addressed, at Division of Hematology/Oncology, New England Deaconess Hospital, 1 Deaconess Road, Boston, MA 02215.

Received 5/ 1/95. Accepted 7/ 6/95.

This article has been cited by other articles:

				T. B. Gernsheimer The Pathophysiology of ITP Revisited: Ineffective Thrombopoiesis and the Emerging Role of Thrombopoietin Receptor Agonists in the Management of Chronic Immune Thrombocytopenic Purpura Hematology, January 1, 2008; 2008(1): 219 - 226. [Abstract] [Full Text] [PDF]

				D. J. Kuter New thrombopoietic growth factors Blood, June 1, 2007; 109(11): 4607 - 4616. [Abstract] [Full Text] [PDF]

				R. G. Romanelli, I. Petrai, G. Robino, E. Efsen, E. Novo, A. Bonacchi, G. Pagliai, A. Grossi, M. Parola, N. Navari, et al. Thrombopoietin stimulates migration and activates multiple signaling pathways in hepatoblastoma cells Am J Physiol Gastrointest Liver Physiol, January 1, 2006; 290(1): G120 - G128. [Abstract] [Full Text] [PDF]

				H. Ehrenreich, M. Hasselblatt, F. Knerlich, N. von Ahsen, S. Jacob, S. Sperling, H. Woldt, K. Vehmeyer, K.-A. Nave, and A.-L. Siren A hematopoietic growth factor, thrombopoietin, has a proapoptotic role in the brain PNAS, January 18, 2005; 102(3): 862 - 867. [Abstract] [Full Text] [PDF]

				K. Ihara, E. Ishii, M. Eguchi, H. Takada, A. Suminoe, R. A. Good, and T. Hara Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia PNAS, March 16, 1999; 96(6): 3132 - 3136. [Abstract] [Full Text] [PDF]

				D. J. Kuter Thrombopoietin: Biology and Clinical Applications Oncologist, February 1, 1996; 1(1): 98 - 106. [Abstract] [Full Text] [PDF]